Abstract
Calcineurin inhibitors are considered the backbone of lung transplant immunosuppression regimens. When used de novo, tacrolimus has been shown to be associated with fewer acute rejection episodes compared to cyclosporine. However, conflicting evidence exists regarding the superiority of tacrolimus or cyclosporine in preventing bronchiolitis obliterans syndrome (BOS). Furthermore, the effect of these drugs on fibroproliferation ultimately leading to BOS remains to be investigated.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
Paper Title
Journal
Date
